Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Teva
Harvard Business School
McKesson
Baxter
Deloitte
Cipla
Fuji
Johnson and Johnson

Generated: October 20, 2018

DrugPatentWatch Database Preview

GADOVERSETAMIDE - Generic Drug Details

« Back to Dashboard

What are the generic sources for gadoversetamide and what is the scope of gadoversetamide freedom to operate?

Gadoversetamide is the generic ingredient in two branded drugs marketed by Liebel-flarsheim and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for gadoversetamide.

Summary for GADOVERSETAMIDE
Synonyms for GADOVERSETAMIDE
(Gadoversetamide) (8,11-bis(carboxymethyl)-14-(2-((2-methoxyethyl)amino)-2-oxoethyl)-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)), gadolinium
(N,N-Bis(2-((carboxymethyl)(((2-methoxyethyl)carbamoyl)methyl)amino)ethyl)glycinato(3-))gadolinium
[8,11-bis(carboxymethyl)-14-[2-[(2-methoxyethyl)amno]-2-oxoethyl]-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)] gadolinium
{N,N-bis[2-([(carboxy-kappaO)methyl]{2-[(2-methoxyethyl)amino]-2-oxoethyl}amino)ethyl]glycinato(3-)-kappaO}gadolinium
131069-91-5
2-[bis[2-[[2-(2-methoxyethylamino)-2-oxoethyl]-(2-oxido-2-oxoethyl)amino]ethyl]amino]acetate; gadolinium(3+)
AC1L9FJP
AC1O5KIJ
AKOS015896615
CHEBI:31644
D01646
D0X0GI
DB00538
DTXSID10156865
gadolinium 8,11-bis(carboxylatomethyl)-14-{2-[(2-methoxyethyl)amino]-2-oxoethyl}-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oate
gadolinium(3+) 2-[bis({2-[(carboxylatomethyl)({[(2-methoxyethyl)carbamoyl]methyl})amino]ethyl})amino]acetate
gadolinium(3+) ion 2-[bis({2-[(carboxylatomethyl)({[(2-methoxyethyl)carbamoyl]methyl})amino]ethyl})amino]acetate
Gadoversetamid
Gadoversetamida
Gadoversetamide (JAN/USP/INN)
Gadoversetamide [USAN:INN:BAN]
Gadoversetamidum
HSDB 7550
I06-2302
LP071524
LS-186531
MRI contrast agent, Mallinckrodt
Optimark
Optimark (TN)
Optimark In Plastic Container
RLM74T3Z9D
SCHEMBL237265
STL451269
UNII-RLM74T3Z9D

US Patents and Regulatory Information for GADOVERSETAMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Liebel-flarsheim OPTIMARK IN PLASTIC CONTAINER gadoversetamide INJECTABLE;INJECTION 020976-003 Dec 8, 1999 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020975-001 Dec 8, 1999 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-003 Dec 8, 1999 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Liebel-flarsheim OPTIMARK IN PLASTIC CONTAINER gadoversetamide INJECTABLE;INJECTION 020976-001 Dec 8, 1999 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for GADOVERSETAMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-002 Dec 8, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020975-001 Dec 8, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-003 Dec 8, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-004 Dec 8, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Teva
Harvard Business School
McKesson
Baxter
Deloitte
Cipla
Fuji
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.